UBS AG, London Branch 5 Broadgate London EC2M 2QSEquity Swap Transaction • November 8th, 2024 • Excalibur LuxCo SARL • Pharmaceutical preparations
This Confirmation evidences a complete and binding agreement between you and us as to the terms of the Transaction to which this Confirmation relates. This Confirmation shall supplement, form a part of, and be subject to an agreement (the “Agreement”) in the form of the ISDA 2002 Master Agreement (the “ISDA Form”) as if we had executed an agreement in the form of the ISDA Form (but without any Schedule) except for the election of (i) English law as the governing law, (ii) EUR as the Termination Currency, (iii) the incorporation of the definitions and provisions contained in annexes 1-18 and Section 6 of the 2002 Master Agreement Protocol published by the International Swaps and Derivatives Association, Inc. and (iv) the additional provisions set out in paragraph 12 (Miscellaneous) below on the Trade Date of this Transaction. In the event of any inconsistency between the terms of this Confirmation and the Agreement, this Confirmation shall govern. All provisions contained in the Agreeme
JOINT FILING AGREEMENTJoint Filing Agreement • November 8th, 2024 • Excalibur LuxCo SARL • Pharmaceutical preparations
In accordance with the requirements of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and subject to the limitations set forth therein, the parties set forth below agree to jointly file the Schedule 13D to which this joint filing agreement is attached, and any subsequent amendments thereto, and have duty executed this joint filing agreement as of the date set forth below.
